Shaker Mousa
Company: Nano-Pharmaceuticals
Job title: Professor ACPHS and Co-Founder
Seminars:
Delving into the Thyrointegrin Antagonist & Cancer Therapeutics 3:40 pm
Considering the challenges in developing novel strategies and the failure of previous avb3 antagonists in cancer therapy Pinpoint the problems with these in order to re-assess the MoAs Overcome these challenges to design novel therapeuticsRead more
day: Day One
An Analysis of Integrins for Nano-Targeted Delivery 1:30 pm
• Looking at the evidence which has demonstrated that nanobiotechnology and nanomedicine have tremendous potential to affect numerous aspects of cancer and other disorders, in both early diagnosis and targeted therapy • The utilization of nanotechnology for the development of new Nano-carrier systems has the potential to offer improved targeted delivery through increased solubility and…Read more
day: Day Two
Roundtable Discussion: 3:15 pm
Finish up your Integrin 101 day with an open discussion with our expert speakers to ensure all your questions are answered, including: The binding of integrins The role of integrins in autoimmune diseases, opthalmic disorders and moreRead more
day: Pre-Conference Focus Day
Chair’s Closing Remarks & End of Day Two 2:00 pm
day: Day Two
Chair’s Opening Remarks 8:50 am
day: Day Two